FAKTOR-OPTIONSSCHEIN - GILEAD SCIENCES | Delayed Deutsche Boerse AG 14:24:49 13/05/2024 BST | ||
| 2.61 EUR | -1.14% |
|
| Current month | -5.38% | ||
| 1 month | +9.54% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/05/24 | 2.61 | -1.14% | 0 |
| 10/05/24 | 2.64 | -6.71% | 0 |
| 09/05/24 | 2.83 | +1.07% | 0 |
| 08/05/24 | 2.8 | +4.87% | 0 |
| 07/05/24 | 2.67 | -3.26% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 13, 2024 at 02:24 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Société Générale
|
| WKN | SB0QUC |
| ISIN | DE000SB0QUC6 |
| Date issued | 04/06/2020 |
| Strike | 73.21 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 8.99 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.7 € |
|---|---|
| Lowest since issue | 1.23 € |
| Spread | 0.03 € |
| Spread % | 1.14% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
65.96
USD
Average target price
82.93
USD
Spread / Average Target
+25.73%
- Stock Market
- Certificates
- Certificat
